Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine ALECSAT - CytoVac

Drug Profile

Cancer vaccine ALECSAT - CytoVac

Alternative Names: ALECSAT; Cytotoxic lymphocyte-based cancer vaccine - CytoVac

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoVac
  • Class Cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Glioblastoma
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 21 Aug 2019 Cytovax plans a phase II trial for Breast cancer in 2019
  • 21 Aug 2019 Cytovax plans a phase II trial for Sarcoma in in the first half of 2021
  • 18 Jun 2019 Phase-II clinical trials in Breast cancer (Metastatic disease, Adjunctive treatment, Late-stage disease) in Denmark (IV) (EudraCT2019-001420-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top